But Marketing 'Variants of Small Effect' Just Doesn't Have the Same Ring

Oct 13, 2008

A column in Forbes warns that services from companies like 23andMe may be today's equivalent of snake oil. 23andMe "is marketing an expensive bit of medical technology with little proof that it will do any good," the article says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

More Common Than Thought

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

Even for Prizes, Women Get Less Money

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

This Week in Nature

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Scramble to Keep the Work Alive

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

Main menu